NEW YORK, NY / ACCESS Newswire / February 12, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want ...

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Intellia Therapeutics, Inc. ("Intellia" or "the Company") (NASDAQ: NTLA) for ...

Intellia Therapeutics has said it will reduce its headcount by 27% this year and shelve early-stage R&D programmes as it puts its resources behind two priority drug candidates. The specialist in ...

Providing a diverse range of perspectives from bullish to bearish, 13 analysts have published ratings on Intellia Therapeutics (NASDAQ:NTLA) in the last three months. The table below offers a ...

We recently compiled a list of the Cathie Wood’s Stock Portfolio: 2025 Stock Picks. In this article, we are going to take a ...

Intellia Therapeutics (NASDAQ:NTLA) did it again. On January 9, 2025, the company announced it would discontinue efforts on NTLA-3001, one of its pipeline gene-editing treatments. It also said it ...

The inducement grant consisted of time-based restricted stock units (“RSUs”) for 21,863 shares of Intellia’s common stock, with one-third of such RSUs vesting on February 1, 2026, 2027 and 2028.

In this article, we are going to take a look at where Intellia Therapeutics Inc. (NASDAQ:NTLA) stands against the other stocks in Cathie Wood's portfolio. Cathie Wood is one of Wall Street's most ...

CAMBRIDGE, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ...